U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

MOUND WORK GROUP

+ + + + +

FRIDAY AUGUST 31, 2012

+ + + + +

The Work Group convened telephonically at 1:30 p.m., Eastern Daylight Time, Josie Beach, Chair, presiding.

PRESENT:

JOSIE BEACH, Chair BRADLEY P. CLAWSON, Member PAUL L. ZIEMER, Member

ALSO PRESENT:

TED KATZ, Designated Federal Official ROBERT BARTON, SC&A
MEL CHEW, ORAU
JOE FITZGERALD, SC&A
KARIN JESSEN, ORAU
JOHN MAURO, SC&A
ROBERT MORRIS, ORAU
JIM NETON, DCAS
L. MICHAEL RAFKY, HHS
BILLY SMITH, ORAU
DON STEWART, ORAU
JOHN STIVER, SC&A

TABLE OF CONTENTS

AGENDA ITEM PAGE	3
Welcome and roll-call	1
Tritides	ō
83.14 status update	2
Status update from NIOSH on Site 63 Profile issues	3
WG recommendations	5

P-R-O-C-E-E-D-I-N-G-S

1:32 p.m.

MR. KATZ: This is the Advisory Board on Radiation and Worker Health Mound Work Group, and let's do roll call.

(Roll call.)

MR. KATZ: So, then, the agenda for this meeting is posted up on the site along with the one paper that is being discussed, which is a paper prepared by NIOSH in response to a set of issues prepared at the last Mound Work Group meeting.

And, Josie, it's your call. Let me just remind everyone when you are not speaking, please mute your phones. If you don't have a mute button, press *6 and then press *6 again to come off of the mute. And please don't put the call on hold at any point, but dial back in if you need to leave. Thank you.

And it's yours, Josie.

CHAIR BEACH: Thanks, Ted.

NEAL R. GROSS

1	So the main focus of this meeting
2	is the tritides and, of course, as Ted
3	mentioned, the tritides paper that came out on
4	August 22nd.
5	It's a two-hour call. If we have
6	time, NIOSH was just going to report out on
7	the 83.14 that will be discussed at the next
8	Board meeting and then just a quick status on
9	the profile issues that we discussed in our
10	June meeting.
11	Jim?
12	DR. NETON: Yes?
13	CHAIR BEACH: On the tritide
14	issue, if you remember, there were four items
15	
16	DR. NETON: Yes.
17	CHAIR BEACH: covered under
18	tritides. And, Jim, I'll let you go ahead and
19	go over your paper, if you would.
20	DR. NETON: Sure. Yes. I will be
21	happy to provide a summary. Everyone should
22	have a copy of the paper that was issued, I

think, August 22nd. It was fairly narrow focused. It addressed the four issues that were raised at the Working Group meeting on June 5th.

I looked, and a copy of our responses is also out on the website. If people don't have access to them, they are available under the Mound Working Group meeting scheduled for today.

So the first issue was to address the treatment of uncertainty in the tritide model, which included a couple of things. One was the use of the 50th percentile versus the 95th percentile in the distribution and also to address some of the ranges of uncertainty that SC&A put forth as possible issues to what are the upper bounds of the exposures.

The first issue that I'll say, you know, we have changed our position, as I indicated at the last meeting, on how we're going to use this tritide model. And the intent now -- and I think it is fairly clearly

NEAL R. GROSS

indicated in the paper -- is to use the 95th percentile of the distribution of the smear samples.

So that's what we're doing. So we don't have to worry about the discussion of the 50th versus 95th. We're just going to use the 95th. And, actually, we're going to use the 95th because it takes care of some of the issues regarding uncertainty.

There are some of these uncertainties that we just can't get our complete hands around. So that we'll just go with the upper values.

I would say that if the model is The uncertainty of what values are accepted. actually used in the input model, in least, do become Site Profile opinion at I would like to talk about a couple the issues that SC&A raised regarding That was their main conclusion, uncertainty. that the two drivers in the dose calculation that impact the upper limit were the choice of

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

the resuspension factor that we chose and the use of the dose conversion factor.

went back and looked at the NUREG/CR-5512, regarding the resuspension And at one point, SC&A was suggesting factor. that we increase the value of the resuspension factor because it is not appropriate, increase it by a factor of five, because it was not based removal data but surface on on contamination measurements.

In my review of that document, though, the parameter was assumed to describe loose contamination. And that's the 5 times 10-5 and that the licensee could use a factor less than that if it's less than that at their facility.

The other point I would like to make regarding the resuspension factor is that we are applying what I would call a chronic resuspension factor versus an acute resuspension factor. And, in doing so, we will assume that a worker has been in an

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	environment with that resuspended material for
2	their entire work year, not just the times
3	when they are there.
4	So the material is not only
5	resuspended on a continuous basis but that the
6	worker is continuously in that area. We think
7	that that justifies the use of the
8	resuspension factor, particularly considering
9	that we're using the 95th percentile value.
10	That briefly summarizes what we're
11	trying to say in response to 1). I don't know
12	if we want to stop after each point and
13	discuss.
14	CHAIR BEACH: Yes. Jim, this is
15	Josie again. Yes, let's stop after each point
16	and let SC&A weigh in and any questions from
17	the Board Members.
18	MR. FITZGERALD: Yes. You know,
19	this is Joe. I think John may want to comment
20	on the resuspension issue. That was one that
21	he spent some time thinking about.

But yes. I think the Work Group

has to remember the context of the concern that we raised when we raised the question of uncertainties. You know, this was during the almost year-long debate over exposure potential, and certainly was some concern that -- certainly it seemed like there was some question about whether it was negligible or not.

And the context of raising these parameters is that the value that one can derive is going to be variable to some extent.

And that was an argument for being careful about ascribing negligibility to something like that, but it has been made moot certainly by the last Work Group meeting, where it was pretty clear that, as Jim pointed out very much in the last meeting, that this is clearly a dose reconstruction methodology. There's no question there's exposure potential. And certainly one can take that as the context of dealing with these uncertainties.

At the time, though, the concern

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1	was you had these uncertainties and
2	theoretical model, but, yet, we're questioning
3	the use of that model as a basis for whether
4	exposure took place.
5	So, anyway, I just wanted to make
6	sure that backdrop you know, we had a
7	yearlong discussion. And we arrived at this
8	discussion with certainties in that context.
9	John, you might want to say a few
10	words, I think, on the resuspension factor. I
11	know that was your specific
12	DR. MAURO: Yes. I would be glad
13	to. I am fine with Jim's answer. The reason
14	I feel that his position is reasonable is
15	really, I brought up this question of
16	removable versus total.
17	Since you're taking swab samples,
18	in effect, what you are really measuring in
19	terms of dpm per meters squared is the
20	removable contamination and not the total
21	contamination.

So I mean, in principle, one could

argue, well, since you're looking at the removable contamination -- and all of the literature on resuspension factors, well, is primarily based on -- well, it's based on, really, a lot of data, some of which was removable and some of which wasn't. So I want to just raise that as an area of possible sensitivity.

However, in the grand scheme of things, 5 times 10-5 is a great number. And, as Jim pointed out, especially if you're going to assume that it's operating at that level continuously and you're working at the 95th percentile on the smear data, so, as far as I'm concerned, I withdraw that comment. And I agree that the number of 5 times 10-5, which I believe is a value that has been adopted in the new approach, is certainly adequately claimant-favorable.

CHAIR BEACH: Okay. This is Josie again. Thank you, John.

Board Members, any

NEAL R. GROSS

comments/questions?

MEMBER CLAWSON: Josie, this is Brad. I just had one question. I was kind of getting a little bit confused of who was going to get this and who wasn't. In NIOSH's proposal, is it everybody that is going to get this or is it -- because I remember we were cutting out certain individuals that -- the so-called ones that we knew had gotten an awful lot -- who is this going to be put towards?

DR. NETON: Brad, this is Jim. The idea, the concept, is that workers we know were directly manipulating the source material, their urinary bioassay results would be treated as if they had inhaled highly insoluble tritide, SMTs. And so they would be provided a very high lung dose primarily.

MEMBER CLAWSON: Okay. So this would be one that would have the tritium bioassay or have you talked in just 11 or 12 that were working directly with this all of

NEAL R. GROSS

the time?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

DR. NETON: No. The ones who were working directly with material would be assumed to have inhaled tritide, a stable metal tritide.

The other workers, who were on tritium bioassay because if you work in the R, one-quarter of the R building or the building, routine tritium you were а on bioassay program, those workers who tritium bioassay would be assigned the dose. We would use the resuspension model from the smear data and assume they inhaled tritides from that source term or we would look at the bioassay data and see what the dose would be if they just inhaled soluble material and picked the higher of the two scenarios.

But the bottom line is anyone who was monitored for tritium would be assigned a dose depending on whether you worked directly with material or you were what I would call a support or ancillary worker.

NEAL R. GROSS

1	MEMBER CLAWSON: Okay. You know,
2	we have talked back and forth. And I
3	apologize, but we have been back and forth so
4	many different ways I wanted to make sure I
5	was completely understanding who was going to
6	receive this and how it was going to be done.
7	I appreciate it.
8	DR. NETON: Okay.
9	DR. MAURO: Jim, can I follow up
10	on that a little bit? I have to make sure I
11	understand. Let's assume we've got a worker,
12	he's not actually working with the tritides
13	and glove boxes and doing that kind of work,
14	but he is there after those activities are
15	completed.
16	DR. NETON: Right.
17	DR. MAURO: And he's working now
18	in an environment where there is tritiated
19	water, which is by far the dominant form of
20	tritium. We all understand that.
21	DR. NETON: Right.

DR. MAURO: But there could also

be surfaces contaminated with tritides. 1 2 DR. NETON: Right. DR. MAURO: Okay? And now he's 3 working there and you collect his urine sample 4 5 and you analyze it. And you see a certain amount of tritium in his urine. 6 I guess what I was thinking -- and 7 correct me if I am wrong -- is that that 8 person then -- you could say, "All right. 9 10 know what the tritium level is in his urine. And we're going to assume that that's a result 11 of inhaling or absorbing tritiated water." And 12 13 reconstruct the doses to the organs of concern on that basis. 14 15 But since he's working in 16 environment where there is also potential for residual levels of tritides, you should add 17 that; in other words, especially if it's a 18 19 respiratory tract. 20 DR. NETON: Yes. That was comment that was raised that Joe put over in 21 an email earlier in the week. 22

1	DR. MAURO: Yes.
2	DR. NETON: I don't know if you
3	had a chance to look at my response.
4	DR. MAURO: I did, and I have to
5	say I didn't understand it.
6	DR. NETON: Well, the idea is that
7	the excretion of tritium in the urine
8	anything that becomes systemic is going to
9	anything that gets into the bloodstream will
10	become incorporated in systemic organs. So if
11	you have a chronic model that you're
12	estimating a certain level of tritium coming
13	out in the urine based on an equilibrium
14	situation, which is what the chronic model
15	would be, then the dose to systemic organs is
16	whatever is in the bloodstream and getting out
17	in the urine. It doesn't matter whether it
18	came from inhalation of soluble tritium or
19	it's contributed to that small fraction that's
20	just coming off of the tritides.
21	DR. MAURO: The place that I feel
	II

that you might be selling this person short is

DR. NETON: Oh, no. If you have a respiratory tract cancer, then the tritide model would give you, this SMT model, would give you -- maximize the lung dose.

DR. MAURO: Stay with me. So if a person has a respiratory tract cancer and, in theory, he has tritium in the urine -- now, any tritium in the urine that you see for this person, as you said, it could be from two sources: one from the tritiated water vapor he inhaled; and also from any tritides he inhaled that were broken up and, of course, But we know that that contribution cleared. to the tritium that's in the urine is going to be minuscule. And so he may very well have inhaled some tritides. And he's got respiratory tract cancer.

Now, if you assume all of the tritium that is the exposure he experienced was entirely from tritiated water, you look at his urine, the reconstructed dose to his

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1 lungs, in this case because it's a lung cancer 2 and you get a lung dose from the inhalation of 3 tritiated water based on the bioassay samples. But I'm saying, but wait a minute. 4 5 This very same person could have inhaled the 6 resuspended tritides, you know, from the 7 swipe. And he's getting both. That's what I'm getting at. He is probably -- and the 8 bioassay sample is not going to give you any 9 10 information on what exposure he experienced from inhaling tritides. 11 It's not 12 going to help you with that. The only thing that will help you 13 reconstruct his lung dose from any possible 14 15 tritides from resuspension that he might have 16 gone is by using your resuspension model for tritides --17 DR. NETON: Yes. Well --18 19 DR. MAURO: unless I'm not 20 thinking about this right, but that is what seems to make sense to me. 21 22 Only for the case of

NETON:

1	lung cancer, which well, prior to 1980,
2	they're presumptives. It's a presumptive
3	cancer and it's covered already. But there
4	may be circumstances where a person with lung
5	cancer wouldn't qualify based on date of
6	employment or something like that.
7	But you have a point. I have a
8	feeling that the dose would be pretty small
9	for the lung from the tritium intake.
10	DR. MAURO: Yes, from the
11	tritiated water, absolutely.
12	DR. NETON: I mean it would be
13	very small. And I highly suspect that the
14	dose would be much larger from the tritide
15	intake.
16	But under that scenario, you are
17	right. And that is worth addressing. I agree
18	with you. I don't think that the suspended
19	organ doses should be added.
20	DR. MAURO: Oh, I agree. Yes.
21	This is
22	DR. NETON: Okay.

1	DR. MAURO: The only reason I
2	raised the question was specifically for the
3	respiratory tract cancer.
4	DR. NETON: I think you have a
5	point.
6	MR. FITZGERALD: And I think, you
7	know, as we all agree, you know, we see an
8	implementation detail. So it's certainly
9	something that can be considered but wouldn't
10	be necessarily holding up the SEC
11	consideration.
12	DR. NETON: Agreed.
13	COURT REPORTER: This is the Court
14	Reporter. Who was just speaking, please?
15	MR. FITZGERALD: Oh, I'm sorry.
16	This is Joe Fitzgerald.
17	Josie, I guess where we end up on
18	this thing is putting the you know, we did
19	express some concerns or at least I expressed
20	some concerns about the, if I can call it,
21	philosophical plausibility, you know, whether
22	one ought to adopt a model in the absence of

actual site monitoring information for the
2 tritides and use this, certainly the tritium.
But we have gone through that in quite a bit
of detail. And, really, it's not germane to
5 what we are talking about here. That's
6 something for the Board to deal with as they
7 have dealt with in the past.
8 But beyond that, I think, as I
9 said earlier, this is no longer a test of
10 exposure potential, which was our biggest
concern about having reliance on a model with
these variables. I think certainly there is
no question these are proven variables. The
methodologies have been out there. And NIOSH
has adopted a conservative, you know, value
16 for these variables.
So I think we're fine with this as
18 it stands right now.
CHAIR BEACH: Okay. And, Paul, do
you have any comments? This is Josie.
21 MEMBER ZIEMER: I was getting off

of the mute button there.

1	I do agree with John's comments on
2	the lung dose, but, as you say, that's kind of
3	a separate issue at this point, you know.
4	CHAIR BEACH: Okay. Thank you.
5	And, Brad, anything else?
6	MEMBER CLAWSON: No. I just want
7	to make sure with who's going to get this,
8	it's been a little bit confusing, but I
9	appreciate it. No more comments. Thanks.
10	CHAIR BEACH: Okay. And this is
11	Josie again. I do agree with this. I do want
12	to understand. Will this become a Site
13	Profile issue and something we will track in
14	our Site Profile discussions, the
15	implementation details like this?
16	DR. NETON: Of this model?
17	CHAIR BEACH: Yes.
18	DR. NETON: Yes, I think so.
19	CHAIR BEACH: Okay. I just wanted
20	to make sure of that.
21	So, with no other comments, Jim, I
22	think we can go on to 1B. And I think we all

agree to accept that 1A is completed. 1 2 DR. NETON: Okay. 3 CHAIR BEACH: Thank you. 4 DR. NETON: Okay. 1B was 5 ascertain the identity of the operators who 6 actually work with the materials and the scrap 7 recovery workers who worked on the material post-1980. And we believe that we have the 8 names of all the workers who handled the 9 10 stable metal tritide, both the operators and 11 the scrap recovery workers. 12 know that Joe earlier in 13 week raised the question about how well we knew the scrap recovery workers, but we have 14 15 gone through the documents that were cited in 16 the SRDB, Site Research Database. And it seems clear to me that the folks who were 17 18 doing recovery were named in scrap 19 documents. I think there were eight people. And this is 20 CHAIR BEACH: Yes. Josie again. I looked. The one document, in 21

particular, was the 107797 that listed --

1	DR. NETON: Exactly.
2	CHAIR BEACH: the eight names.
3	DR. NETON: Yes. It's a lot my
4	recollection, I think they're all there.
5	CHAIR BEACH: Well, there was
6	another time period referenced. That was in
7	R-108. And then there was another one
8	referenced in SW-8. That was prior to before
9	it was moved, but I didn't see any names
10	listed there. And I'm wondering if you're
11	assuming it's the same names or
12	DR. NETON: Well, maybe Mel could
13	help me out with this, but my impression was
14	that the scrap recovery was all conducted in
15	that one room.
16	DR. CHEW: That is correct, Jim.
17	CHAIR BEACH: Well, based on the
18	documents you cited, there was one that
19	discussed that it had been moved.
20	MR. FITZGERALD: Well, you know
21	go ahead.
22	CHAIR BEACH: No. Go ahead.

MR. FITZGERALD: This is Joe

Fitzgerald again. I participated in two to

three interviews. And, you know, we had gone

through in some detail back in 2008, at the

beginning of this inquiry on tritides.

In the context of the interviews

and the discussion with the production side,

and the discussion with the production side, you know, this was before Brant and I did our research down in Oak Ridge to nail down what the circumstances and history were on the scrap recovery.

So the focus -- and you recall hearing Brant say at a number of Work Group meetings, you know, I know the -- I guess it was either 10 or 11 operators by name that were involved in the production.

So the context was production.

And, as the interview notes suggest, these are the production operators. When we got into the recycle, you know, this was after those interviews.

And then the discussion was who --

NEAL R. GROSS

know, in my opinion, based the interviews, these earlier interviews, is that it's some subset of those eight, no question. They weren't additional people, but said question for you, Jim, as I in clarification note, was, other than the one individual that's actually named in one of the in fact, the interviews; SRDB that you actually cited in your response to my note, as having quote, "ran it" in R-108, it's just a little ambiguous as to what subset. Was it just that one individual? In other words, he just didn't run it. What, did he manage it? Did he have additional numbers? Or does it matter?

Are you going to assume that those eight were the individuals that would have been exposed in the entire production process, whether it's the front end or the back end. They would be given credit for whatever doses in R-108 occurred.

You know, it just wasn't clear how

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

you were going to approach that, because I think there is some ambiguity. There is not as much precision on the named individuals in the back end and in the 1980s as there were in the production phase. I think they're the same people, but I'm not sure if it's a small subset, one person, a few people, or, actually, all eight were equally involved in the scrap recovery.

DR. NETON: I was not part of the interview process. So I'm a little bit at a disadvantage here, but our intent would be that any of the named individuals would be considered to have handled stable metal tritides.

But my reading of the SRDB-107797, if you go through it, it says, "Now let's move on, and please describe to me scrap recovery."

And in part of that sequence, there is a listing of, I think, eight names that were provided.

It doesn't say anything about --

NEAL R. GROSS

1	it doesn't qualify any particular way, to my
2	recollection, in the
3	DR. CHEW: Hey, Jim, this is Mel.
4	Let me just jump in for a second. Joe and
5	Working Group, there are two SRDBs you need to
6	look at, and they're in the report: 107797
7	and 55962.
8	The specific question was asked,
9	"Who worked in R-108 (scrap recovery)?" And
10	in total, there were nine technicians and
11	seven professionals who worked in development,
12	production, and scrap recovery. Quite a bit
13	of the technicians worked in scrap recovery.
14	And they were identified in one of the two
15	SRDBs I had mentioned. I think there are a
16	total of like six or seven in total.
17	MR. FITZGERALD: Okay.
18	DR. CHEW: So that's all clear.
19	MR. FITZGERALD: So Mel, I'm
20	looking at 797. And I see the reference to
21	the text. They're listed by name.
22	DR. CHEW: Right. And they said

1	it's R-108, Joe. And I think you had
2	confirmed with Brant that the tritide of
3	interest only showed up in 1984.
4	MR. FITZGERALD: Right. And 797,
5	can you help me on where the operator,
6	operator or operators, are named for
7	DR. CHEW: Well, the operators
8	were mentioned in 55962.
9	MR. FITZGERALD: Okay. But I'm
10	just saying that, really, what is in 797 is
11	the text.
12	DR. CHEW: Right.
13	MR. FITZGERALD: Okay.
14	DR. CHEW: You have to put the two
15	
16	MR. FITZGERALD: Yes.
17	DR. CHEW: You have to put the two
18	together and then sort out because some of
19	them, technicians, also worked on the
20	development and production. And we sorted all
21	through, put all of the names together. There
22	are several people, not to be named, that

1 worked both in development and the 2 recovery, but the one that you're looking at 3 is the one that was clearly asked for and in R-108 4 identified that worked on 5 And those are the technical -recovery. 6 MR. FITZGERALD: Now, just for 7 clarity's sake -- and this was the reason I had raised this as a clarification question. 8 562 9 In the one, there was an explicit statement that one individual ran it. 10 11 the operator that you are referring to in that 12 one, in 962? 13 DR. CHEW: Yes. Yes. 14 MR. FITZGERALD: Okay. 15 DR. CHEW: That person was 16 responsible for running the operation along with the technician. And I think there were 17 one or two professionals that also joined in 18 19 on the scrap recovery. But primarily, the 20 scrap recovery was run by technicians with the

person that you had mentioned as being the

person responsible.

21

1	MR. FITZGERALD: Okay. That detail
2	isn't quite as clear in here, but certainly
3	you have the one operator in 562 in the SRDB.
4	And then you have lists of so-called
5	technicians.
6	But you're saying you went through
7	the list of technicians, married that up with
8	the other name, and between the two, you could
9	nail down who not the technicians or
10	support staff because those are covered under
11	the model, but the named, so-called named
12	operators, you can actually finger more than
13	that one individual who was named in 562.
14	DR. CHEW: Correct.
15	MR. SMITH: This is Billy Smith.
16	The SRDB number is 55962.
17	MR. FITZGERALD: 962, right, 962.
18	MR. SMITH: Right. It lists in
19	that particular document eight technicians
20	that worked in R-108. In 107797, it listed 8
21	people in that document, 7 of which are
22	professionals. There's one technician listed

1	in that list that's not in the list shown on
2	55962.
3	MR. FITZGERALD: Well, not to get
4	this more confusing than it's becoming, but
5	962, the listing at the bottom of the first
6	page, where there's eight individuals listed,
7	those are sort of a combination of technicians
8	and chemists and other operators. So you've
9	got a mixed bag there.
10	And what is listed in 797 are
11	unequivocally the rad techs in 108. That's
12	pretty clear.
13	DR. CHEW: They were not
14	necessarily rad techs. They were chem techs.
15	MR. FITZGERALD: Or chem techs.
16	It's just the techs in 108.
17	DR. CHEW: Correct. Correct.
18	MR. FITZGERALD: So that's what
19	you have there.
20	DR. CHEW: Correct.
21	MR. FITZGERALD: All I was trying
22	to do is beyond the techs and the support
	NEAL D. CDOCC

1	folks, trying to figure out, other than the
2	one individual who is fingered in 962 as being
3	the one who ran it, were there any other
4	operators? And I guess what I hear, Mel, you
5	saying that yes, you went through this, even
6	though I don't quite I don't quite see it
7	in this collection of interviews, but you went
8	through this and figured out there were some
9	other non-techs, non-support people besides
10	this one individual, who would have been
11	involved with 108.
12	DR. CHEW: That is true.
13	MR. FITZGERALD: And you know him
14	by name?
15	DR. CHEW: Yes, sir.
16	MR. FITZGERALD: Okay. Because
17	that is not jumping out from these three
18	interview notes, but that is fine. That is
19	the question. As we have done, as Brant and
20	you had done on the production side, the front
21	end, have you done that on the back end?

And that was the original question

1	that came out of the Work Group the last time.
2	And obviously we wouldn't have raised it, nor
3	would the Work Groups have spent time on it if
4	it were in these old interviews because we
5	certainly had access to them. So it wasn't
6	clear at that time.
7	So you're saying you do have that
8	information?
9	DR. CHEW: Yes, sir.
10	CHAIR BEACH: Okay. So this is
11	Josie. I have a question, probably for Mel.
12	Would it be any problem to contact the one
13	individual who is listed that ran the
14	operation just to verify names so that we are
15	not missing anyone, with a phone call
16	interview?
17	DR. CHEW: I will let Jim give me
18	the authority to do so.
19	CHAIR BEACH: Yes.
20	DR. NETON: I don't see any reason
21	why we couldn't do that.
22	CHAIR BEACH: Joe, what do you

think?

MR. FITZGERALD: Well, I think that would be fine. I think it would be very quick. But, again, it's not so much the technicians or the support people, but just this one individual is very knowledgeable, I think very credible. And if the confirmation is that either that person was the only person or there may have been one or two others, that would be, I think, a very credible and useful answer to inform how you assign those doses for the back end, for that one year.

CHAIR BEACH: Right.

DR. CHEW: Let me add to that,

Joe. Not only -- there was a person or two,

but we need to make sure we have their names.

MR. FITZGERALD: Yes. Like I said, I'm pretty sure it's within the groupings that we're familiar with for the production side, but this was, you know, a few years later. So it's possible there might have been an additional person that wasn't

1	part of that original cohort. Since this
2	individual is still around, I think that is a
3	very helpful way to confirm this and put this
4	to bed.
5	But, you know, Josie, with that
6	confirmation, I think we're fine.
7	CHAIR BEACH: Okay. So offline
8	could we set up a conference call and involve
9	SC&A, NIOSH to confirm those names, hopefully
10	before the Board meeting?
11	DR. NETON: I don't know about
12	that.
13	CHAIR BEACH: I guess it doesn't
14	have to be done before, but it would be
15	helpful to have those names confirmed as early
16	as possible.
17	DR. NETON: Well, we can try. Put
18	it that way.
19	CHAIR BEACH: Okay.
20	MR. FITZGERALD: And even if it
21	can't be scheduled before the Board meeting, I
22	think Josie can report that there is every

1 good reason to think that that be 2 confirmed and this can be put to bed. CHAIR BEACH: Okay. I agree with 3 Brad or Paul? 4 that. 5 MEMBER CLAWSON: Yes, Josie, this 6 is Brad. I had a question for Mel. You were 7 talking about technicians, and then you were 8 talking about operators. And then you were talking about professionals. 9 Could you 10 clarify on what you are classifying as a professional? 11 Well, I'll say this 12 DR. CHEW: here, 13 correctly Brad. I don't want misquote. The professionals would be degreed 14 15 people who would be considered researchers or 16 principal investigators. And the technicians would be the supporting role for them. 17 Т think that is how Mound separates them, but I 18 19 don't know that for sure. 20 think we basically really shouldn't -- an operator could be both a 21 22 professional and a technician, as you well

know, Brad. And so I think that's the separation.

MEMBER CLAWSON: Well, right.

Mel, that is what I was trying to get because when we use the term "professional," you know, I understand about the degreed people, everything else like that.

My issue is sometimes when we are talking about this and we say "professionals," it doesn't limit these people accurately because some of the professionals were also classified as technicians or so forth.

I always wanted to make sure that when we set this up that -- because when I'm thinking professionals I'm thinking more of the scientists, researchers, or whatever else like that. And I just wanted to make sure that we're looking at the technicians and operators and that we're separating this out, that we've got the right people that were in there.

My other question was, my

NEAL R. GROSS

1	understanding was, I understand that scrap
2	recovery was done in this room, but my
3	understanding is that in the earlier years,
4	that it went through a re-drumming process
5	before it got there because the drums were an
6	issue and were having problems. They used to
7	be stored out on a pad was my understanding at
8	Mound.
9	How long was this product actually
10	at Mound before it was processed or
11	repackaged?
12	DR. CHEW: I don't know that
13	answer.
14	MEMBER CLAWSON: The reason being
15	is that in these interviews, with this
16	interview we have been talking to, my
17	understanding was this stuff was kind of like
18	the wayward child nobody really wanted. And
19	it moved from one area to another area until
20	it got to be such a problem.
21	And then it went through 109 and

was eventually taken care of because I want to

make sure that everybody here understands these drums and so forth had problems. And this is why they were going through this process.

And I hope that we can -- you

And I hope that we can -- you know, I know that we're looking at just the scrap recovery in this 109 room. And are we looking at the whole history of where this was at and how it got there and how long it was around there?

DR. CHEW: I'll tell you what I can share with you now, Brad. The main production and development basically stopped in about the 1974 time frame and that has been clearly dated.

And you're right. It sat around and the material was put in drums until the scrap recovery was started in 1984 on the material.

And based on that, if you look at the model that we're putting together. Any exposures to that -- I don't want to speak for

NEAL R. GROSS

Jim, but I'll let Jim jump in -- would be, any potential would be given to the ancillary workers, who might have been tertiarily exposed. And we would use that model to bound that dose for them.

MEMBER CLAWSON: Because Mel, you know my understanding of this, right? You're looking at, unfortunately, probably a different standpoint than what you guys are, but in our interviews and so forth with the workers or technicians, whatever you want to — all of them knew of this product. Many of them have dealt with this. And it was an upcoming project to be able to take care of this because it had become a problem child.

And I want to make sure that we've got some way to be able to cover the other people that handled it, dealt with it because they would have troubles with the drums deteriorating and going on to there.

I think that we have got a fairly good handle on the 109 room.

NEAL R. GROSS

1 DR. CHEW: 108. 2 MEMBER CLAWSON: 108 room, 3 But, anyway, I just want to make sure that we've got the other people that handled this 4 5 and how are we going to address them. 6 I just want to add a 7 DR. CHEW: point to you, Brad. On this particular case, 8 as you know, this particular material was 9 10 highly classified and highly valued by both Mound and DOE. And so I think there was a 11 12 great interest in making sure that the drums 13 were not going to be misused and mishandled. NETON: Yes. And, Brad, I 14 DR. 15 just want to make a point here. Remember that 16 there is already a Class at Mound that covers workers up through 1980. 17 Right. 18 MEMBER CLAWSON: 19 NETON: It effectively covers 20 all those workers who had worked with tritides because it's anyone who was monitored 21

for tritium, which by definition is all of

1	those workers. So even though the Class was
2	not constructed to cover those workers
3	thereby, they're de facto in the Class
4	already.
5	MEMBER CLAWSON: And, Jim, I
6	appreciate that. I'll be right honest with
7	you. We have got so many different Classes
8	going there, sometimes I cannot keep track of

DR. NETON: I have trouble myself, but it really is sort of an odd situation that before 1980, all of these workers are covered already by the radon Class, because of the radon Class by the way it was defined.

all the different Classes and who is being

I just wanted --

MEMBER CLAWSON: Okay. I know that we have had a couple of interviews and these people have dealt with these drums and so forth before they were eventually taken care of. I just wanted to make sure that we did have them covered in this.

If this is the fact, then it won't

NEAL R. GROSS

9

10

11

12

13

14

15

16

17

18

19

20

21

22

covered.

be an issue. I just wanted to make sure and kind of clarify that because truthfully -- and I apologize for my ignorance, but I really have -- especially with several different Site Profiles, I have a hard time remembering who was in where and how we were going to do this. And Mound has been a particularly interesting one from that standpoint.

Thank you.

MR. SMITH: This is Billy Smith.

I need to make a comment here. One of the things that we're doing here I think is mixing apples and oranges.

One of the things about the tritium recovery system in Mound, Mound had the tritium recovery for all of DOE. And so they processed tritium coming from other sites that were not necessarily tritides in the recovery process. And, hence, most of that would have been in the form of either HgO or organically bound tritium, but they did all of the tritium recovery there.

NEAL R. GROSS

1	In terms of the tritide recovery,
2	one of the critical people that we interviewed
3	indicated that at most and this term was
4	there was not more than a bucket full of
5	tritides that went through the recovery
6	operation.
7	CHAIR BEACH: Okay. Thank you,
8	Billy, for that clarification.
9	If there's nothing else on 1B,
10	Jim, we're ready for 1C, addressing the
11	identified gaps in the swipe data.
12	DR. NETON: Right. SC&A
13	determined there were gaps in the swipe data
14	that were used. And we embarked on trying to
15	figure out the significance of those gaps by
16	looking at a couple of different things.
17	One is that we interviewed a
18	couple of workers with knowledge of operations
19	at Mound and specifically were trying to
20	figure out, did they have any knowledge
21	related to unusual operations or cessation of

increasing operations during

22

operations or

those gap periods? And neither person interviewed could come up with any reason why the exposure would be different in those periods. Nor could they determine why we wouldn't have the smear data. They just appear to be missing.

But, nonetheless, they didn't recall any reason why production, for example, would have increased dramatically during those gap periods and thereby increasing the potential for contamination exposure.

The second thing was we looked at the urinalysis data. And what that told us time that complete over we have а very urinalysis record. If production quantities did increase, then the urinary output would go up concomitantly because tritide exposure is also associated with just soluble tritium. And, as we report in the write-up, there was no evidence that there was anything like that that occurred.

The third point that I would

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	mention is that SC&A did point out a few
2	reports that could be relied on to fill in
3	some of the gaps so the gap period themselves,
4	if we take advantage of that information, will
5	be somewhat less than what was presented in
6	the first report.
7	So the bottom line is that we
8	don't really see any reason why we can't fill
9	in the gap period with the adjacent data and
10	proceed accordingly.
11	That's all I really have to say.
12	CHAIR BEACH: Okay. This is Josie
13	again. Thanks, Jim.
14	Joe, anything on the SC&A side?
15	MR. FITZGERALD: Well, I was going
16	to defer a bit to you know, Bob Barton has
17	spent a great deal of time looking at that
18	very question. Bob, I know you've looked at
19	the response. What do you think?
20	MR. BARTON: Well, thanks, Joe.
21	Yes, this is Bob Barton with SC&A.
22	As Jim mentioned, there are sort

of three facets to this. I mean, one of them is there are a few more reports in there that kind of close the gaps a little bit, but there will also be some data gaps.

The second one was the use of the bioassay, which is sort of an indirect measure because, you know, as we know, urinalysis can't really directly reflect what kind of tritide exposures there would be out there, but Ι certainly appreciate the influence because, you know, we at SC&A, we use that all There isn't really a quantitative the time. way to directly answer the question. So that's good. I mean, it builds certainly a weight of evidence argument.

The best one, though, in my mind is the interviews which are talked about in this latest report actually talking with the people who were involved and saying, "Listen, we have these gaps here, here, and here. Is there any reason to think that we can't use, you know, the data before and after to sort of

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

reflect what was probably going on during 1 2 those gaps?" 3 My only comment there is it's not really cited or I'm not familiar with the 4 5 interview. I guess it happened recently. 6 CHAIR BEACH: Yes. The only thing I 7 MR. BARTON: would say there is it would really kind of put 8 this issue to bed if we could show which 9 10 interviews occurred and where they kind of There's no reason to think we 11 "Yes. say, 12 can't cover these data gaps with the swipe 13 data that happened before and afterwards." I guess I would ask, Jim, these 14 15 were recent interviews? 16 DR. NETON: Yes. These were in the last -- geez, I've lost track of time, but 17 in the last month or something. 18 19 MR. FITZGERALD: Yes. They might not be summarized and through DOE yet. 20 think that was the intent was, to get those 21 22 documented.

1	DR. NETON: Right.
2	MR. FITZGERALD: So
3	DR. NETON: Those certainly will be
4	available once they are all reviewed and
5	publishable.
6	MR. BARTON: Okay. And that's
7	really what we were looking for there, was
8	just some sort of confirmation that we don't
9	have any reason to worry about those periods
10	where we don't have swipe data. I think that
11	pretty much puts that issue to bed, at least
12	in my mind.
13	CHAIR BEACH: Okay. Thanks, Bob.
14	Paul, Brad, anything? Any
15	questions?
16	MEMBER CLAWSON: Josie, this is
17	Brad. Not at this time, I don't.
18	MEMBER ZIEMER: This is Ziemer. I
19	don't have any questions.
19 20	don't have any questions. CHAIR BEACH: Paul, you cut out a

1	comfortable with the approach. I think it
2	makes sense and is a logical approach. And
3	once the interviews are confirmed, I think we
4	are okay.
5	CHAIR BEACH: Okay. Thank you.
6	And I agree with that.
7	I thought I read and I probably
8	did read. That latest one is out on SRDBs,
9	that you conducted with Jim and Joe. Well, I
10	don't know if you were there, Jim, but Joe?
11	DR. NETON: Yes. I was on the
12	phone.
13	CHAIR BEACH: Yes.
14	MR. FITZGERALD: I had not seen
15	it, but I could be there by now. It's been
16	about four weeks.
17	CHAIR BEACH: Okay. So
18	DR. NETON: Oh, there is
19	"documented communication with" yes. It's
20	reference 2. I'm trying to see where.
21	CHAIR BEACH: I read so many of
22	these close together, but I'm pretty sure I

1	thought I read those interview notes.
2	MR. FITZGERALD: Okay. Well, if
3	they're up, then that answers Bob's comment,
4	because that would provide those comments.
5	CHAIR BEACH: Okay. So let's move
6	on to the last one under tritides, D, the
7	reconstruction during D&D.
8	DR. NETON: Yes. Right. This has
9	to do with D&D coverage. I guess it sort of
10	depends on what you consider, you know, when
11	the D&D era started, but all indications are
12	that the active what was quote-unquote
13	"full-blown" D&D didn't occur until the late
14	'90s.
15	And by that time, the technology
16	shortfall for monitoring for tritides was
17	pretty well established. Mound embarked on a
18	fairly rigorous program of breathing zone air
19	samples followed up by scanning electron
20	microscopy and also used urine samples to
21	ascertain the soluble urine tritium intakes.

We feel in that time period the

1	coverage was pretty good. I was even
2	surprised. The scanning microscopy I thought
3	was a little over the top, but if you look,
4	there's a procedure that we attached or not
5	a procedure but interoffice correspondence
6	that was issued in 1997 that outlined all of
7	the precautions that were taken and the
8	monitoring conditions that were in place for
9	monitoring tritides during this era. And they
10	indeed are pretty rigorous. So that's our
11	position for the D&D era.
12	CHAIR BEACH: Okay. Thanks, Jim.
12 13	CHAIR BEACH: Okay. Thanks, Jim. Joe, anything on the SC&A side
13	Joe, anything on the SC&A side
13 14	Joe, anything on the SC&A side there?
13 14 15	Joe, anything on the SC&A side there? MR. FITZGERALD: Yes. Josie,
13 14 15 16	Joe, anything on the SC&A side there? MR. FITZGERALD: Yes. Josie, you'll recall that this goes back a few
13 14 15 16	Joe, anything on the SC&A side there? MR. FITZGERALD: Yes. Josie, you'll recall that this goes back a few years. Actually, it goes back to maybe some
13 14 15 16 17	Joe, anything on the SC&A side there? MR. FITZGERALD: Yes. Josie, you'll recall that this goes back a few years. Actually, it goes back to maybe some of the Site Profile review that we did.

they were very careful from the operational

standpoint to button up that particular facility when it was no longer needed and used operators to do a lot of the D&D back when that was decommissioned. This was well before the terminal D&D for the entire site. And it was done very carefully.

Our issue really was more from some interview feedback we had gotten about the terminal D&D, where they seemed to have picked up some reading that suggested the tritides were not in the operational areas but really in the ductwork, that kind of thing, that they found.

I know there were some additional interviews. We weren't involved in those, but additional interviews where at least one individual who had provided that perspective had clarified that that was not what he had meant.

Now, you know, that was pretty much the source of our questions on that. And we have not certainly had the opportunity to

NEAL R. GROSS

go back and satisfy ourselves from that standpoint. Again, we weren't involved in those interviews.

But I would not at this point see essential this for settling out the as question of the tritides during the operating period of the plant. This is kind analogous to the residuals question that you have at some of the AWEs. There is this sort lingering question. Even though program procedures and whatnot were pretty stringent, and I think the RWP suggests that as well, that one that was included was implementation such that there was no real exposure potential during the D&D phase.

We have not really gone back to that question, really, since the Site Profile in terms of the tritide question. That might be something in the Site Profile context that, as we look at some additional information, we ought to see if there's anything else that would stand as sort of operational

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	information, experience, incidents. We
2	haven't seen any yet, but I wouldn't argue
3	this thing unless we do.
4	So that's kind of a little bit of
5	an open end, but not one that should hold this
6	up.
7	CHAIR BEACH: Okay, Joe. This is
8	Josie again. Thanks for that summary.
9	Paul or Brad, any comments?
10	MEMBER CLAWSON: This is Brad.
11	You know, I agree with Joe on this. I was
12	involved in some of those interviews. And I
13	think we'll you know, we really haven't
14	looked at it, as Joe has said, because we've
15	got these other issues taken care of.
16	I just want to make sure that we
17	don't lose it somewhere. and it sounds like
18	we're not. So I'm fine at this time.
19	MEMBER ZIEMER: Yes. And this is
20	Ziemer. I am fine at this time, too. I think
21	you are still going to track this, right?
22	CHAIR BEACH: Yes. This is Josie

1	again. I put that down as a Site Profile
2	issue to track along with part of A.
3	MR. FITZGERALD: Yes. And just
4	again, this came from a health physicist
5	during the D&D phase that expressed the fact
6	that they surprisingly came upon what appeared
7	to be some tritide contamination in ductwork.
8	And, again, I think in a
9	re-interview, that was clarified as not to be
10	the case, but that's kind of all we've got at
11	this point. So there hasn't been any further
12	corroboration, but I think that's unsettled at
13	this point.
14	
15	MEMBER ZIEMER: Joe, this is
16	Ziemer. Do you know how they identified that
17	as being tritide at that point?
18	MR. FITZGERALD: Well, what the
19	interview documentation and, again, this
20	goes back four or five years ago. So it was
21	an old one. They were using an alpha probe
22	and thought they were or alpha-beta probe.

I guess it was both alpha and beta. They were picking up what they thought was Pu, polonium. I'm trying to remember which.

But it turned out not to be the case. And it looked like it was, in fact, at the energy level they were looking at perhaps tritide because at that time there was a consciousness on tritide, but that was it. It was almost an anecdotal type of thing.

They didn't do any further analysis. It was sort of left that way. And we had not talked to this individual since to do that. Brant, I think, did. And based on Brant's questioning, he apparently -- I'm not sure how he -- whether he recanted it or just said that it was misunderstood. I don't know, but certainly the response was that he no longer felt that way.

So that's kind of where it is. It really hasn't been pursued much further than that. There isn't anything, any incident information, any documentation that we have

1	found that would corroborate that they were
2	picking up tritides in the ductwork or in
3	anything that was connected to those
4	facilities. So that's all we have, is really
5	the interview data. It's not a very strong
6	thing.
7	So that's what I'm saying. I
8	think it should be handled as a matter of
9	course. If there's anything, any new
10	documentation, anything that's substantial
11	that surfaces, that's something I think we
12	ought to bring back to the Work Group. But I
13	wouldn't certainly give it any more than what
14	we're doing for the remaining Site Profile
15	issues to see if there's any additional
16	documentation left, any records that we
17	haven't looked at. That would be about it.
18	DR. CHEW: Josie, this is Mel. I
19	would like to make a point of clarification.
20	CHAIR BEACH: Yes?
21	DR. CHEW: That discussion with

again, Joe, you are right on. We did go back

1	and discuss it with another health physicist.
2	We want to make sure we bear in
3	mind that when they mention tritides, the
4	majority of the tritides at Mound were in the
5	soluble form. And so when you mentioned
6	tritides, you are saying all categories. The
7	ones that we are obviously focusing in is the
8	tritide of special interest here.
9	CHAIR BEACH: Okay. This is Josie
10	again. Thanks, Mel.
11	And, with that, I don't think we
12	need to do a formal vote. I think based on
13	what I have heard in the last hour
14	conversation, all three of the Board Members
15	present at this Work Group meeting agree that
16	the tritides issue is complete other than the
17	two items that we talked about tracking in a
18	Site Profile sense.
19	Ted, is that correct?
20	MR. KATZ: I'm sorry. I was on
21	mute.
22	Yes. You don't need to vote. I

1	mean, everybody has spoken pretty clearly
2	about all of these issues.
3	CHAIR BEACH: Okay. Thank you.
4	And if there is nothing else on
5	tritides, I am going to say that that is
6	closed.
7	And if we could just take time to
8	have NIOSH report out on the next two issues
9	on our agenda? Start with the 83.14, just an
10	update of what is happening there.
11	DR. NETON: Okay. These will be
12	brief. The 83.14, to refresh your memory, is
13	to add a Class of workers for the couple of
14	years where we discovered that we didn't have
15	logbooks for tritium sampling.
16	Now we have a litmus case for that
17	83.14. The report had been drafted. And I
18	just received word that it has been sent out
19	for ADC review.
20	CHAIR BEACH: Okay.
21	DR. NETON: The report is done.
22	Once it comes back from ADC review, we will

1	distribute it, hopefully early next month,
2	which starts tomorrow. And we should be good
3	to go there.
4	I will be presenting that at the
5	Advisory Board meeting in Denver.
6	CHAIR BEACH: Okay. Thank you.
7	DR. NETON: So expect that report
8	to come out as soon as I don't know what
9	turnaround time we're going to get for that
10	report, but I imagine it's pretty fast because
11	I can't imagine there's much in there that's
12	controversial.
13	CHAIR BEACH: Right.
13 14	CHAIR BEACH: Right. DR. NETON: The second point.
14	DR. NETON: The second point.
14 15	DR. NETON: The second point. What was I going to talk about the second
14 15 16	DR. NETON: The second point. What was I going to talk about the second
14 15 16 17	DR. NETON: The second point. What was I going to talk about the second CHAIR BEACH: The second point on
14 15 16 17	DR. NETON: The second point. What was I going to talk about the second CHAIR BEACH: The second point on DR. NETON: Oh, Site Profile
14 15 16 17 18	DR. NETON: The second point. What was I going to talk about the second CHAIR BEACH: The second point on DR. NETON: Oh, Site Profile issues. Yes. I'm sorry.

1	CHAIR BEACH: Yes.
2	DR. NETON: So my mind is
3	wandering.
4	The Site Profile issues, ORAU had
5	put together a completion schedule to get to
6	us draft responses by the end of September.
7	Once it goes through the various review
8	processes internally, we expect to be able to
9	start talking about all those responses
LO	sometime later in October for the remaining
L1	Site Profiles, which there are a number.
L2	CHAIR BEACH: Right. Yes, there
L3	
L4	DR. NETON: Now, I didn't get a
L5	breakdown as to how each one might be
L6	complete. I just sort of got a lump sum date.
L7	If it's preferable, I could try to get a
L8	little more fine-tuned breakdown of the
L9	schedule, but right now I don't expect to be
20	done until later in October.
21	CHAIR BEACH: Okay. No. That's
22	fine, Jim. And possibly when you have more of

1	a breakdown and know when you will be ready to
2	discuss it, we can plan a Work Group.
3	DR. NETON: Right. Because
4	honestly I don't think they're all going to
5	come due at exactly the same minute. You
6	know, there
7	CHAIR BEACH: No.
8	DR. NETON: are a lot of varied
9	issues out there. I forgot how many, but
10	there's something like 20, I believe.
11	CHAIR BEACH: Yes. There are
12	quite a few. And I wouldn't expect them to
13	come due at the same time. But it would be
14	nice to have them all pretty much done and
15	DR. NETON: Yes.
16	CHAIR BEACH: and just wait.
17	DR. NETON: Later in October.
18	CHAIR BEACH: Great. All right.
19	Any other questions for Jim, other Board
20	Members?
21	MEMBER CLAWSON: Josie, this is
22	Brad. I don't have any at this time.

1	CHAIR BEACH: Okay. Paul, I think
2	you might have spoken.
3	MEMBER ZIEMER: I said I have no
4	questions.
5	CHAIR BEACH: Okay. So, with
6	that, Ted, I think we've completed our work
7	today and we can adjourn.
8	MR. KATZ: Let me just check with
9	you, Josie, about we have Mound on the
10	agenda for the Board meeting in Denver.
11	CHAIR BEACH: Right.
12	MR. KATZ: And I have it broken out
13	in two parts because we have the 83.14, for
14	which we're given a half an hour. It sounds
15	like that is easily enough to address that.
16	CHAIR BEACH: Yes.
17	MR. KATZ: Then immediately
18	following, I have a whole hour and a half
19	right now for the rest of the Mound SEC
20	petition. And that's where I need some
21	feedback from you and the Group with respect

to how much time do you actually think the

Board will need to discuss the rest of
wrapping up Mound?
CHAIR BEACH: Well, I don't think
we would need more than a half hour, but that
depends on if I am just going to report out
and vote or if Jim would like to comment and
Joe would like to add for the tritides. I
guess that determines what the Group thinks.
MR. KATZ: Okay. And, just to let
you know more, what I have is, I have Jim or
the agenda because, just as he has reported to
you, I would think you would want him to
report to the full Board on the tritides.
CHAIR BEACH: Right. Okay.
MR. KATZ: So I have him on the
agenda before you. And then I have you.
It seems like you know, what
time is it now? It's 2:36. What time did we
start this call?
CHAIR BEACH: We started at 1:30.
MR. KATZ: 1:30?
CHAIR BEACH: About an hour.

1	MR. KATZ: So it's probably going
2	to go a little quicker with the full Board
3	because you have done sort of the detailed
4	vetting. So I would say Jim's piece and back
5	and forth with the Board probably can get done
6	in half an hour, do you think, Jim?
7	DR. NETON: I'm not 100 percent
8	clear what you really want me to present. I
9	mean, I presented today our responses to the
10	SC&A comments.
11	MR. KATZ: Right.
12	DR. NETON: But it would seem
13	better to sort of go over our proposed model
14	for tritides, the swipe data, the whole thing,
15	and include how we're going to do it and that
16	sort of thing.
17	MR. KATZ: I agree, Jim. I agree.
18	I assume you will be putting to bed the issues
19	that the Board realized were open as well.
20	DR. NETON: Yes, yes. But I think
21	I need to take a step back and say, "Well,
22	here is our proposed model. And here is what

1	we are going to do."
2	MR. KATZ: No, I totally agree.
3	They're going to need more context than the
4	Work Group does. So I'm just asking you, do
5	you think you want a half an hour for that,
6	including back and forth with the Board, or do
7	you think you'll need more?
8	DR. NETON: It's a fairly simple
9	model. I mean, it's not very complex.
10	MR. KATZ: Okay.
11	CHAIR BEACH: So 30 minutes, Jim,
12	you think that would cover it?
13	DR. NETON: Oh, absolutely plenty.
14	CHAIR BEACH: Yes. And mine won't
15	take very long either.
16	MR. KATZ: Okay. So do you think
17	maybe another 30 minutes for your piece and
18	back and forth with the Board will do it,
19	Josie?
20	CHAIR BEACH: Yes, yes.
21	MR. KATZ: Okay. So then I'll cut
22	the whole period down from an hour and a half

1	to an hour, then.
2	CHAIR BEACH: Yes. And I would
3	even say 45 minutes, but that's based on
4	it's hard to determine how many questions will
5	come out of that.
6	MR. KATZ: Yes. That's true.
7	CHAIR BEACH: Okay.
8	MR. KATZ: Okay.
9	CHAIR BEACH: That sounds good.
LO	Okay. Anything else?
L1	(No response.)
L2	CHAIR BEACH: Then I think our
L3	work is complete and we can adjourn. Thank
L4	you, everyone.
L5	(Whereupon, the above-entitled
L6	matter was concluded at 2:38 p.m.)
L7	
L8	
L9	
20	
21	
2	